{
    "symbol": "OPK",
    "quarter": 2,
    "year": 2022,
    "date": "2022-08-04 19:29:08",
    "content": " With that brief overview, I'd like to turn the call over to Elias, and then Jon will discuss BioReference\u00e2\u0080\u0099s quarterly results and initiatives. With that brief overview, I'd like to turn the call over to Elias, and then Jon will discuss BioReference\u00e2\u0080\u0099s quarterly results and initiatives. Frost, we're currently in exploration of interest and discussions with several pharma companies for potential partnerships surrounding this platform. So now let me turn it over to Jon Cohen, who will speak about BioReference Laboratories. Frost, we're currently in exploration of interest and discussions with several pharma companies for potential partnerships surrounding this platform. So now let me turn it over to Jon Cohen, who will speak about BioReference Laboratories. Moving to operating results, our diagnostic segment reported revenue of $186.8 million compared to $397.2 million for the 2021 period. Moving to our Pharmaceutical segment, we reported revenues of $123.1 million for the second quarter, compared to $45.2 million for the 2021 period. Operating income from our Pharmaceutical segment was $55.4 million for the second quarter of 2022, while the comparable period of 2021 reported an operating loss of $13.7 million. Turning to the consolidated financial results of the second quarter, we reported an operating loss of $10.7 million compared to operating income of $5.6 million in the 2021 period. Net loss for the second quarter of 2022 includes the $71.2 million non-cash mark-to-market adjustment or declines in this price of Sema4s, common stock resulting in a loss of $101.7 million or $0.14 per diluted share for the quarter compared to a net loss of $16.2 or $0.03 per diluted share for the 2021 period."
}